Longitudinal analysis revealed divergent trajectories: F9 levels declined post-treatment, while COMP increased, consistent with therapeutic response and disease progression.<h4>Conclusions</h4>Our findings support the development of a dual-marker, proteomics-based plasma assay for noninvasive GBM detection and real-time monitoring. The gene discussed is COMP; the disease is glioblastoma.